QLGN Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 1.80%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $0.00

Qualigen Therapeutics Insider Trading History Chart

Qualigen Therapeutics Share Price & Price History

^$3.41

▼ -0.08 (-2.29%)

As of 04/2/2025 05:00 PM ET

Days: 30 | 90 | 365

Qualigen Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/22/2022	Michael S. Poirier	CEO	Buy	600	$28.50	$17,100.00	3,984
6/14/2022	Amy S. Broidrick	Insider	Buy	600	$31.00	$18,600.00	690

SEC Filings (Institutional Ownership Changes) for Qualigen Therapeutics (NASDAQ:QLGN)

3.18% of Qualigen Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Qualigen Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
8/10/2023	Meitav Investment House Ltd.	27,293	$3.21M	0.0%	N/A	0.540%
7/24/2023	Meitav Investment House Ltd.	27,293	$3.21M	0.1%	N/A	0.540%
5/10/2022	Ground Swell Capital LLC	43,251	$29K	0.1%	N/A	0.123%
1/31/2022	Commonwealth Equity Services LLC	87,510	$93K	0.0%	-36.4%	0.298%
11/15/2021	Franklin Resources Inc.	82,000	$0.11M	0.0%	N/A	0.283%
11/15/2021	GSA Capital Partners LLP	78,687	$0.10M	0.0%	N/A	0.271%
10/14/2021	Hatton Consulting Inc.	27,195	$35K	0.0%	-26.9%	0.094%
8/16/2021	State Street Corp	104,314	$0.21M	0.0%	N/A	0.362%
8/13/2021	Renaissance Technologies LLC	113,911	$0.23M	0.0%	N/A	0.395%
8/13/2021	Geode Capital Management LLC	168,702	$0.34M	0.0%	+10.3%	0.585%
8/13/2021	Vanguard Group Inc.	1,023,911	$2.04M	0.0%	+239.9%	3.551%
8/11/2021	Commonwealth Equity Services LLC	137,510	$0.27M	0.0%	+10.9%	0.477%
8/2/2021	Hatton Consulting Inc.	37,195	$74K	0.1%	-35.0%	0.129%
6/23/2021	StoneX Group Inc.	13,442	$36K	0.0%	N/A	0.047%
5/17/2021	Price T Rowe Associates Inc. MD	107,500	$0.29M	0.0%	N/A	0.373%
5/12/2021	Geode Capital Management LLC	152,898	$0.41M	0.0%	+24.3%	0.530%
5/11/2021	Vontobel Holding Ltd.	25,300	$68K	0.0%	N/A	0.088%
5/10/2021	GSA Capital Partners LLP	18,031	$49K	0.0%	N/A	0.063%
5/5/2021	Hatton Consulting Inc.	57,195	$0.15M	0.1%	N/A	0.198%
5/4/2021	Commonwealth Equity Services LLC	124,049	$0.33M	0.0%	+716.3%	0.538%
4/28/2021	Perkins Capital Management Inc.	31,652	$85K	0.0%	N/A	0.137%
4/22/2021	HighMark Wealth Management LLC	80,094	$0.22M	0.2%	N/A	0.347%
2/17/2021	Cetera Investment Advisers	40,275	$0.12M	0.0%	+140.2%	0.175%
2/11/2021	Northern Trust Corp	38,731	$0.12M	0.0%	N/A	0.168%
2/9/2021	Wells Fargo & Company MN	30,577	$92K	0.0%	+19,010.6%	0.133%
2/9/2021	Bank of New York Mellon Corp	20,824	$63K	0.0%	N/A	0.090%
2/5/2021	BlackRock Inc.	317,818	$0.96M	0.0%	+1.2%	1.378%

Data available starting January 2016

See Full Table

Qualigen Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.

Today's Range

Now: $3.41

$3.06

$3.50

50 Day Range

MA: $3.38

$3.01

$4.34

52 Week Range

Now: $3.41

$2.96

$29.44

Volume

77,444 shs

Average Volume

107,590 shs

Market Capitalization

$2.51 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.75